Savara Faces Stock Decline Amid Phase 3 Trial Updates
By ATTN Desk · Editorial oversight: Sean Han
Savara Inc. (NASDAQ: SVRA)
Introduction
Savara Inc. (ticker: SVRA) is a clinical-stage biopharmaceutical company headquartered in the United States and listed on the NASDAQ exchange. Founded in 2007, the company focuses on developing inhaled therapies for rare respiratory diseases. Its lead product candidate, MOLBREEVI (molgramostim inhalation solution), is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) currently in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). The FDA and EMA have conditionally accepted “MOLBREEVI” as the trade name for molgramostim.
Corporate Structure
- Headquarters: United States
- Employees: 51–200 (LinkedIn)
- Management Experience:
- Leadership team with backgrounds in orphan drug development, pulmonary medicine, and commercial operations at companies such as Shire, Insmed, and Strongbridge Biopharma.
- Executives hold advanced degrees in business, law, medicine, and pharmaceutics; several have led companies through IPOs and drug approvals.
- Board of Directors:
- Includes executives with expertise in biotechnology, law, and commercial sectors from firms like Roche, Genentech, and Jazz Pharmaceuticals.
Recent Developments and News
- April 9–12, 2025 (Leipzig, Germany): Presentations of top-line IMPALA-2 Phase 3 data at the 65th Congress of the German Society of Pneumology (DGP).
- April 11–13, 2025 (Tokyo, Japan): Presentations of IMPALA-2 data at the 65th Annual Meeting of the Japanese Respiratory Society (JRS).
- May 8, 2025 (New York City): 1×1 investor meetings and discussion at the Citizens Life Sciences Conference.
- May 13, 2025: Filed Quarterly Report on Form 10-Q for the period ending March 31, 2025.
- May 15, 2025: Amended Schedule 13G/A filed, reporting that Frazier Life Sciences Public Fund, L.P. holds 6,745,296 shares, representing 3.9% of common stock.
- May 20, 2025 (New York City): 1×1 investor meetings and corporate presentation at H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference.
- May 27, 2025: Current Report on Form 8-K filed (items 8.01 and 9.01).
- June 4, 2025 (New York City): 1×1 meetings and presentation at the Jefferies Global Healthcare Conference at 9:20 AM ET.
Financial and Strategic Analysis
| Metric | Value |
|---|---|
| Share Price (2025-05-27) | $2.03 |
| Day’s Change | –28.52% |
| Volume | 5,269,450 |
| Market Cap (intraday) | $350.9 million |
| Net Income (TTM) | –$102.17 million |
| Total Cash (MRQ) | $173.3 million |
| Total Debt/Equity (MRQ) | 20.08% |
| Beta (5Y Monthly) | 0.44 |
| EPS (TTM) | –$0.49 |
- Cash Position & Runway: With $173 million in cash and equivalents, Savara's funding focused on late-stage clinical trials remains critical.
- R&D Spend: Ongoing expenses primarily support the Phase 3 IMPALA-2 trial and activities related to regulatory submissions.
- Debt Levels: A debt/equity ratio of 20.08% indicates moderate leverage in line with industry standards.
- Ownership: Institutional investors, including Frazier Life Sciences, hold significant stakes, reflecting investment interest in the aPAP program.
Market Position and Industry Context
- Disease Focus: Autoimmune pulmonary alveolar proteinosis is a rare respiratory disorder characterized by surfactant accumulation in the lungs, with no approved inhaled GM-CSF treatments available.
- Competitive Landscape: There are few clinical-stage competitors targeting aPAP; however, other rare-disease biopharmaceutical companies are pursuing pulmonary and immunology therapies.
- Regulatory Pathway: Orphan drug designation and conditional trade-name acceptance by FDA/EMA for MOLBREEVI aim to facilitate approval and market access following successful Phase 3 results.
- Commercial Potential: Although the patient population is small, there is a significant unmet need; pricing and reimbursement will depend on demonstrating clinical benefits and economic value.
TL;DR
- On 2025-05-27, Savara’s share price closed at $2.03 (–28.52%) with a trading volume of 5.3 million shares.
- Phase 3 IMPALA-2 data have been presented at the DGP (April 9–12) and JRS (April 11–13), highlighting reductions in surfactant burden and quality of life improvements for aPAP patients.
- The company conducted investor events on May 8 (Citizens Life Sciences), May 20 (H.C. Wainwright BioConnect), and June 4 (Jefferies Global Healthcare).
- Financial reports (10-Q filed May 13) show a TTM net loss of $102 million, cash reserves of $173 million, and a debt/equity ratio of 20%.
- Upcoming catalysts include final Phase 3 data, regulatory submissions for MOLBREEVI, and additional investor presentations through mid-2025.